Company Filing History:
Years Active: 1990-1991
Title: Innovations by Yoshikuni Itoh: Contributions to Expectorants
Introduction
Yoshikuni Itoh is an esteemed inventor based in Tomisato, Japan, known for his contributions to pharmaceutical innovations. With a record of two patents, he has demonstrated significant advancements in the field of expectorants, focusing on compounds with enhanced stability and minimal side effects.
Latest Patents
Yoshikuni Itoh's latest patents include innovative formulations of expectorants comprising hydroxyalkylcysteine derivatives. The first patent describes an expectorant composed of a hydroxyalkylcysteine derivative characterized by a specific chemical formula. This formulation is notable for its stability, low toxicity, and an excellent expectorant effect, making it an invaluable asset in respiratory treatment. The second patent elaborates on novel hydroxyalkylcysteine derivatives with a broader range, offering similar characteristics of stability and effectiveness as an expectorant.
Career Highlights
Yoshikuni Itoh is currently associated with Ss Pharmaceutical Co., Ltd., where he continues to innovate and contribute to the pharmaceutical industry. His expertise has played a crucial role in refining expectorant formulations, aimed at providing safer and more effective solutions for patients suffering from respiratory ailments.
Collaborations
In his professional journey, Yoshikuni Itoh collaborates with talented individuals such as Hiroyuki Mizuno and Chikako Kiyohara. Together, they work on various projects that leverage their combined knowledge and skills to advance the development of effective pharmaceutical products.
Conclusion
Yoshikuni Itoh stands out as an influential figure in the pharmaceutical sector, particularly in the development of expectorants. Through his innovative patents, he has made significant strides in creating effective and safe treatments for respiratory conditions, showcasing the importance of continuous research and collaboration in the field of medicine.